Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Clinical trial tests COXEN model to predict best treatment for bladder cancer

August 14, 2014 By EurekAlert

Imagine being able to match a cancer’s genes to the best treatment. That’s the promise of COXEN (CO eXpression ExtrapolatioN) – a computer program that looks at a panel of cancer genes in a patient’s tumor to predict whether it will respond to chemotherapy. Now a clinical trial recently approved by the National Cancer Institute will open at the University of Colorado Cancer Center and nationally via the Southwest Oncology Group (SWOG) to test the COXEN model in bladder cancer – can it predict which cancers will and which cancers will not respond to two common chemotherapies?

“It’s an important question. Chemotherapy before surgery or radiation has been shown to have benefit overall, but picking which specific patients benefit and which have no benefit is currently not possible. If we treat a bladder cancer with chemotherapy and the tumor doesn’t respond, we’ve lost valuable months in which we could have done surgery or radiation and have exposed the patient to toxicity,” says Dan Theodorescu, MD, PhD, professor of Urology and Pharmacology, director of CU Cancer Center and a developer of COXEN.

The COXEN program is powered by data known for what is called the NCI-60. Basically, extensive genetic and drug testing has been done against a panel of 60 cell lines curated by the National Cancer Institute, representing a range of human cancers. Because we know the genetics of cancers that respond to certain drugs, we can extrapolate this knowledge to predict new cancers that will respond to these drugs – based on genetic similarity between cancers, we can make accurate inferences about what will work and what will not work even for cancers not represented among the NCI-60, such as bladder cancer. In fact, because COXEN depends on genes and not on tumor types like “lung” or “bladder” or “breast” to make its predictions, it could be applied across various cancers, based only on genetic similarity.

“Bladder cancer isn’t rare, but there hasn’t been a major medical breakthrough in treating bladder cancer 20 years,” says Thomas Flaig, MD, medical director of the CU Cancer Center Clinical Investigations Shared Resource, associate professor of medicine at the University of Colorado School of Medicine, and national chair of the current SWOG clinical trial. “We have new, targeted treatments for lung cancer, breast cancer, and others, but so far there hasn’t been a good way to select patients with the best chance of responding to traditional chemotherapies. COXEN could allow us to better target these therapies, predicting what will work and what will not based on a cancer’s genetic structure for individual patients.”

The phase 2 randomized trial now underway will use tissue from a biopsy before surgery. Researchers will then examine the cancer’s genetic structure. In this case, patients will have been randomized to one of two currently accepted chemotherapeutic regimens, namely Gemcitabine plus Cisplatin or MVAC, a 4 drug combination. Researchers will watch patient outcomes to discover if the COXEN algorithm predicted the most useful drug more often than current methods. If successful, future trials will allow COXEN to choose bladder cancer treatment proactively, and could be expanded to many additional cancer types.

“This is a big deal for three reasons,” Flaig says. “First, it could help us correctly assign patients to chemotherapy versus immediate local therapy with surgery or radiation in bladder cancer. Second, it could help us direct chemotherapy in many other human cancers if proven here. And third, it could represent the first advance in a disease that has lagged far behind many others in the modern era of molecularly-driven cancer care.”

The COXEN trial will enroll 184 bladder cancer patients at the CU Cancer Center and at other NCI clinical trials sites around the country.

Original release: http://www.eurekalert.org/pub_releases/2014-08/uocd-ctt081314.php

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech